John M. Leonard's most recent trade in Intellia Therapeutics Inc was a trade of 34,146 Common Stock done at an average price of $9.2 . Disclosure was reported to the exchange on Jan. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.21 per share. | 05 Jan 2026 | 34,146 | 1,013,339 (2%) | 0% | 9.2 | 314,485 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 11 Dec 2025 | 49,959 | 1,127,074 (2%) | 0% | 6.8 | 341,220 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 49,959 | 8,557 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.49 per share. | 11 Dec 2025 | 49,959 | 1,077,115 (2%) | 0% | 9.5 | 474,111 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.47 per share. | 11 Dec 2025 | 32,832 | 1,044,283 (2%) | 0% | 9.5 | 310,919 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 8,557 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 11 Dec 2025 | 8,557 | 1,047,485 (2%) | 0% | 6.8 | 58,444 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.59 per share. | 11 Dec 2025 | 5,355 | 1,038,928 (2%) | 0% | 9.6 | 51,354 | Common Stock |
| IQVIA | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,592 | 15,375 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 196,000 | 196,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 136,000 | 1,077,115 (2%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 26,807 | 941,115 (1%) | 0% | 12.2 | 326,509 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 7,850 | 967,922 (1%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 7,850 | 0 | - | - | Restricted Stock Unit | |
| IQVIA | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 1,047 | 13,783 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 163,929 | 163,929 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 113,586 | 960,072 (1%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | M. John Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 19,223 | 846,486 (1%) | 0% | 29.5 | 566,310 | Common Stock |
| Intellia Therapeutics Inc | Leonard John M. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,848 | 7,850 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | M. Leonard John | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,848 | 865,709 (1%) | 0% | - | Common Stock | |
| IQVIA | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 1,063 | 12,736 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 128,631 | 128,631 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 91,036 | 857,861 (1%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 6,673 | 766,825 (1%) | 0% | 37.2 | 248,302 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 7,848 | 773,498 (1%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 7,848 | 15,698 | - | - | Restricted Stock Unit | |
| IQVIA | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 995 | 11,673 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 170.00 per share. | 30 Aug 2021 | 44,735 | 719,305 (1%) | 0% | 170 | 7,604,950 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 37,833 | 90,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 155.00 per share. | 30 Aug 2021 | 37,833 | 719,305 (1%) | 0% | 155 | 5,864,115 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 37,833 | 757,138 (1%) | 0% | 14.6 | 551,605 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.46 per share. | 30 Aug 2021 | 28,750 | 748,055 (1%) | 0% | 23.5 | 674,475 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 28,750 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 27,167 | 127,833 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 27,167 | 758,109 (1%) | 0% | 14.6 | 396,095 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 30 Aug 2021 | 15,985 | 764,040 (1%) | 0% | 18.3 | 292,526 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 15,985 | 11,515 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 155.70 per share. | 30 Aug 2021 | 15,567 | 730,725 (1%) | 0% | 155.7 | 2,423,782 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 11,637 | 212,501 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 30 Aug 2021 | 11,637 | 730,942 (1%) | 0% | 13.4 | 155,936 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 154.98 per share. | 30 Aug 2021 | 7,428 | 746,292 (1%) | 0% | 155.0 | 1,151,191 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 156.96 per share. | 30 Aug 2021 | 4,758 | 725,967 (1%) | 0% | 157.0 | 746,816 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 157.75 per share. | 30 Aug 2021 | 3,123 | 722,844 (1%) | 0% | 157.7 | 492,653 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 159.18 per share. | 30 Aug 2021 | 2,598 | 720,246 (1%) | 0% | 159.2 | 413,550 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.66 per share. | 30 Aug 2021 | 2,334 | 753,720 (1%) | 0% | 153.7 | 358,642 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 152.81 per share. | 30 Aug 2021 | 2,055 | 756,054 (1%) | 0% | 152.8 | 314,025 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 159.98 per share. | 30 Aug 2021 | 725 | 719,521 (1%) | 0% | 160.0 | 115,986 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 160.69 per share. | 30 Aug 2021 | 216 | 719,305 (1%) | 0% | 160.7 | 34,709 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 27,139 | 224,138 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 23 Aug 2021 | 27,139 | 746,444 (1%) | 0% | 13.4 | 363,663 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 151.54 per share. | 23 Aug 2021 | 18,874 | 727,570 (1%) | 0% | 151.5 | 2,860,166 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.08 per share. | 23 Aug 2021 | 8,165 | 719,405 (1%) | 0% | 153.1 | 1,249,898 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.52 per share. | 23 Aug 2021 | 100 | 719,305 (1%) | 0% | 153.5 | 15,352 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 22,682 | 251,277 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 19 Aug 2021 | 22,682 | 741,987 (1%) | 0% | 13.4 | 303,939 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 150.46 per share. | 19 Aug 2021 | 9,726 | 732,261 (1%) | 0% | 150.5 | 1,463,374 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 151.56 per share. | 19 Aug 2021 | 6,993 | 725,268 (1%) | 0% | 151.6 | 1,059,859 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 152.30 per share. | 19 Aug 2021 | 5,963 | 719,305 (1%) | 0% | 152.3 | 908,165 | Common Stock |
| IQVIA | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 934 | 10,678 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 15,937 | 15,937 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 13 Apr 2021 | 15,937 | 719,305 (1%) | 0% | 13.9 | 221,206 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 13 Apr 2021 | 10,000 | 703,368 (1%) | 0% | 6.8 | 68,300 | Common Stock |